NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Gerresheimer 2025 Financial Results and Strategic Outlook FAQ
Gerresheimer published its audited 2025 annual financial statements, reporting stable revenue of EUR 2.3 billion and an adjusted EBITDA margin of 16.8%. The company is progressing with the sale of Centor, refinancing, and a transformation program to improve margins.
Revenue was EUR 2.3 billion, adjusted EBITDA was EUR 384 million, organic revenue growth was +0.3%, and the adjusted EBITDA margin was 16.8%.
The publication was postponed due to internal investigations regarding revenues and accounting practices in financial years 2024 and 2025. The issues have been reviewed and corrected.
Revenue reached EUR 1.346 billion (up 5.2% pro forma currency-adjusted), driven by strong demand for drug delivery devices. Adjusted EBITDA was EUR 315 million with a margin of 23.5%.
The division experienced subdued demand for primary packaging for cosmetics and pharmaceutical oral liquids, leading to declines in organic revenue and adjusted EBITDA compared to the prior year.
Revenue is expected in the lower half of EUR 2.3 to 2.4 billion, with an adjusted EBITDA margin between 17% and 18%.
The company is proceeding with the sale of its U.S. subsidiary Centor, planning comprehensive debt refinancing, and continuing the implementation of its transformation program (gto) to gradually improve margins.
CFO Wolf Lehmann stated that the audited publication sends a positive signal and that transparency and compliance are top priorities, with steps being taken to improve the financial situation.
Bormioli Pharma contributed approximately EUR 167 million to revenue and EUR 30 million to adjusted EBITDA in its first-time consolidation.